Autopsy report · NCT00547482

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

“Protocol design under review.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 300 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

MetaCure (USA), Inc.

Sponsor type

Industry

Conditions

Type 2 Diabetes Mellitus; Overweight

Interventions

TANTALUS(TM) System

Participants

300

Sites

10

Countries

United States

Trials that died the same way

• Bacteriophage Therapy in Patients With Prosthetic Joint Infections
  “Changes to protocol design” (81% match in meaning)
• Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce Risk of Acute Kidney Injury
  “revised and combined with another protocol” (69% match in meaning)
• Graft Take and Microbiology in Burns
  “Technical problems with protocol.” (69% match in meaning)
• Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
  “Replaced by another protocol” (68% match in meaning)
• RCT for Women With a Persisting Pregnancy of Unknown Location
  “A new protocol was written to replace this protocol.” (66% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.